LDK378
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Conditions
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Trial Timeline
Jun 1, 2012 โ Jan 1, 2016
NCT ID
NCT01634763About LDK378
LDK378 is a phase 1 stage product being developed by Novartis for Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK). The current trial status is completed. This product is registered under clinical trial identifier NCT01634763. Target conditions include Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01947608 | Pre-clinical | Completed |
| NCT02450903 | Phase 2 | Completed |
| NCT02040870 | Phase 1/2 | Completed |
| NCT01950481 | Phase 1 | Completed |
| NCT01685138 | Phase 2 | Completed |
| NCT01685060 | Phase 2 | Completed |
| NCT01634763 | Phase 1 | Completed |
| NCT01283516 | Phase 1 | Completed |
Competing Products
20 competing products in Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E7050 | Eisai | Phase 1 | 33 |
| SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) | Syros Pharmaceuticals | Phase 1 | 25 |
| Cixutumumab | Eli Lilly | Phase 1 | 33 |
| [203Pb]VMT-ฮฑ-NET + [212Pb]VMT-ฮฑ-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [212Pb] VMT-ฮฑ-NET | Perspective Therapeutics | Phase 1 | 25 |
| ZN-c3 + Bevacizumab + Pembrolizumab | Zentalis Pharmaceuticals | Phase 1 | 25 |
| IMC-18F1 | Eli Lilly | Phase 1 | 33 |
| OKI-179 | OnKure Therapeutics | Phase 1 | 25 |
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 25 |
| LY2875358 + Erlotinib + Gefitinib | Eli Lilly | Phase 1 | 33 |
| Tomivosertib (eFT-508) | eFFECTOR Therapeutics | Phase 2 | 44 |
| SPYK04 | Chugai Pharmaceutical | Phase 1 | 33 |
| AUBE00 + Cetuximab | Chugai Pharmaceutical | Phase 1 | 33 |
| LUNA18 + Cetuximab | Chugai Pharmaceutical | Phase 1 | 33 |
| ERY974 | Chugai Pharmaceutical | Phase 1 | 33 |
| DS3610a | Daiichi Sankyo | Phase 1 | 33 |
| Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oral | Daiichi Sankyo | Phase 1 | 33 |
| DS-1123 | Daiichi Sankyo | Phase 1 | 33 |
| DS-8201a | Daiichi Sankyo | Phase 2 | 52 |
| DS-5573a | Daiichi Sankyo | Phase 1 | 33 |